Literature DB >> 22304485

Mineralocorticoid receptors mediate cardiac remodelling in morphine-dependent rats.

Azadeh Mesripour1, Abishek Iyer, Lindsay Brown.   

Abstract

Acute morphine administration decreases cardiac responses to ischaemic injury. This project has determined whether induction of morphine dependence in rats by gradually increasing morphine doses for 21 days induces structural and functional changes in the cardiovascular system because of mineralocorticoid receptor activation, as morphine increases plasma corticosterone concentrations. Morphine-dependent rats showed ventricular hypertrophy, increased collagen deposition in the left ventricle together with an increased ventricular stiffness and increased plasma malondialdehyde concentrations without changes in systolic blood pressure or thoracic aortic responsiveness. These parameters were attenuated or normalised in morphine-dependent rats treated with spironolactone (50 mg/kg/day) from days 14-21. These results suggest that morphine dependence induces ventricular remodelling and increased oxidative stress that can be prevented by the mineralocorticoid receptor antagonist, spironolactone.
© 2012 The Authors Basic & Clinical Pharmacology & Toxicology © 2012 Nordic Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22304485     DOI: 10.1111/j.1742-7843.2012.00860.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  2 in total

1.  Effects of low-dose spironolactone combined with irbesartan on cardiac hypertrophy induced by pressure overload in rats.

Authors:  Jingtao Ma; Hongxue Zhang; Huicai Guo; Yanfang Xu
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

2.  In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator.

Authors:  Prabhat Singh; Bhupesh Sharma; Surbhi Gupta; B M Sharma
Journal:  Psychopharmacology (Berl)       Date:  2014-07-26       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.